0
0
A groundbreaking advance in the treatment of chronic kidney disease (CKD) associated with type 1 diabetes (T1D) has emerged with the drug finerenone, offering renewed hope for millions affected by this serious condition. Presented recently at the American Society of Nephrology’s Kidney Week 2025 in Houston, findings from the Phase 3 FINE-ONE clinical trial demonstrated that finerenone significantly reduces markers of kidney damage in people with T1D and CKD, with a safety profile consistent with previous studies in type 2 diabetes (T2D) populations. This marks the first major therapeutic development in over 30 years for T1D patients facing kidney complications, a population historically underserved by available treatments.
Key Findings and Clinical Impact
The global FINE-ONE trial enrolled around 220 adults with T1D, CKD indicated by elevated urine albumin-to-creatinine ratio (UACR), and moderate kidney function impairment. Finerenone, a non-steroidal mineralocorticoid receptor antagonist (nsMRA), demonstrated a statistically significant reduction in UACR compared to placebo over a six-month treatment period. UACR is a critical indicator of kidney damage; lowering this marker correlates with delayed progression of CKD, reduced risk of kidney failure, and a lower incidence of cardiovascular events—common and life-threatening complications in T1D patients with kidney disease.
Dr. Hiddo J. Heerspink of the University Medical Center Groningen, principal investigator of the study, emphasized the significance: “This is the first time in three decades that a drug has shown a beneficial risk profile with the potential to offer long-term protection to kidneys in patients with type 1 diabetes, possibly also extending cardiovascular benefits.” The trial’s safety outcomes matched those seen in finerenone’s prior approval for CKD treatment in type 2 diabetes, with excellent tolerability and no new safety concerns reported.
Background and Unmet Need
Chronic kidney disease affects up to 30% of individuals with T1D, increasing significantly with age and duration of disease. Kidney damage in diabetes arises largely from harmful hormonal activity—particularly aldosterone—that promotes inflammation and fibrosis within kidney tissues. Until now, treatment for CKD in type 1 diabetes has relied on decades-old approaches, primarily renin-angiotensin system (RAS) inhibitors, which have limited efficacy and fail to fully address the pathogenic mechanisms.
While new medications have revolutionized CKD management in T2D, patients with T1D have been underrepresented in clinical research, in part due to concerns about side effects. Finerenone works by blocking aldosterone’s mineralocorticoid receptor more selectively and safely than older steroidal MRAs, reducing kidney inflammation and fibrosis without the hormonal side effects common to earlier agents.
Expert Perspectives
Jonathan Rosen, Ph.D., Research Director at Breakthrough T1D, highlighted the clinical value: “Few treatment options exist for people with type 1 diabetes and kidney disease. The FINE-ONE trial’s positive results signal an important advance, addressing a major unmet medical need and providing hope for better kidney health and quality of life for many patients.”
Independent nephrologists not involved in the trial echoed enthusiasm but advised cautious optimism. Dr. Maria Gonzalez, a nephrologist specializing in diabetic kidney disease, noted, “This is a landmark trial that may change practice once regulatory approvals expand. However, longer-term outcomes and real-world data will be crucial to fully establish the scope of kidney and cardiovascular protection finerenone offers in type 1 diabetes.”
Public Health and Practical Implications
With CKD a leading cause of kidney failure and cardiovascular morbidity in people with diabetes, finerenone’s approval for T1D patients could shift the treatment paradigm. Early intervention with finerenone may slow disease progression, reduce hospitalizations related to kidney and heart complications, and improve overall lifespan and quality of life. For patients and healthcare providers, this underscores the importance of regular kidney function monitoring and considering finerenone as part of an integrated diabetes care plan once available.
Importantly, finerenone’s tolerability profile facilitates its use alongside existing treatments like RAS inhibitors and emerging therapies such as SGLT2 inhibitors, which have complementary mechanisms to protect kidney function and cardiovascular health.
Limitations and Considerations
Despite the promise shown, the FINE-ONE study primarily measured surrogate markers (UACR) over a relatively short duration of about seven months. While UACR reduction correlates with better long-term outcomes, definitive evidence on hard endpoints like kidney failure or mortality from extended follow-ups is awaited. Additionally, finerenone’s use requires monitoring for potential hyperkalemia (elevated potassium levels), a known risk of mineralocorticoid receptor antagonists, though incidence appears low with this drug.
Further research will also clarify cost-effectiveness, accessibility, and the best patient profiles for finerenone therapy within diverse healthcare settings.
Conclusion
Finerenone represents a transformative advance in the management of kidney disease among patients with type 1 diabetes, ushering in a new chapter after decades of therapeutic stagnation. Backed by robust clinical trial data, it offers a promising option with the potential to reduce kidney damage and cardiovascular risks safely. As regulatory reviews proceed, it is poised to become an essential tool in combating one of the most serious complications of type 1 diabetes, benefiting patients and healthcare systems alike.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
